Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Explore existing data to uncover cancer risk insights, seeking to understand outcomes like survival and treatment response.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $350,000 direct costs per year, for up to 5 years (R01 mechanism; actual needs should be justified in the application).
Summary: Supports secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes, including risk prediction, survival, and treatment response.
Key Information: Clinical trials are not allowed; up to 10% of the budget may be used for new data generation solely for validation of key findings.
Description
This NIH funding opportunity, led by the National Cancer Institute (NCI) and co-sponsored by the National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), and National Institute of Dental and Craniofacial Research (NIDCR), invites R01 applications for innovative secondary analysis and integration of existing datasets to advance understanding of cancer risk and related outcomes. The initiative aims to address key scientific questions in cancer research by leveraging and analyzing existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular data.
Applicants are encouraged to propose new research aims, advanced analytical methods, or novel combinations of datasets that enable exploration of important questions in cancer etiology, risk prediction, prevention, survival, and treatment response. The program is designed to maximize the value of existing data resources and promote cost-effective research that can lead to new insights and hypotheses in cancer control and population sciences.
